FOXO4-DRI represents a precision approach to clearing senescent cells — the “zombie cells” that accumulate with age and drive chronic inflammation and tissue dysfunction. Unlike broad-spectrum senolytics, it specifically targets the molecular mechanism that keeps senescent cells alive.
Research Applications
Senescent cell clearance, aging biology, tissue rejuvenation, kidney function restoration, and senolytic therapy development.
Dosage Information (Research Use)
Mouse research: 5 mg/kg IV, administered three times per week for several weeks. Human dosing not established. Research use only.
Reconstitution & Handling
Reconstitute with sterile water or BAC water. Higher concentrations may be needed due to mg/kg dosing.
Half-Life & Pharmacokinetics
Extended compared to L-amino acid peptides due to D-retro-inverso modification. Specific pharmacokinetics not fully characterized.
Reported Observations in Literature
Mouse studies showed transient weight loss during treatment, with recovery after completion. Selective for senescent cells — should not affect healthy tissue.
Key Research References
- Baar MP, et al. “Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging.” Cell. 2017